

**CONFLICT-OF-INTEREST STATEMENT:** A conflict-of-interest statement is required for all article and study types. In the interests of transparency and helping reviewers to assess any potential bias in a study's design, interpretation of its results or presentation of its scientific/medical content, the Baishideng Publishing Group (BPG) requires all authors of each paper to declare any conflicting interests (including but not limited to commercial, personal, political, intellectual, or religious interests) in the title page that are related to the work submitted for consideration of publication. In addition, reviewers are required to indicate any potential conflicting interests they might have related to any particular paper they are asked to review, and a copy of signed statement should be provided to the BPG in PDF format.

**Sample wording:** [Name of individual] has received fees for serving as a speaker, a [position; such as consultant and/or an advisory board member] for [name(s) of organization(s)]. [Name of individual] has received research funding from [name(s) of organization(s)]. [Name of individual] is an employee of [name(s) of organization(s)]. [Name of individual] owns stocks and/or shares in [name(s) of organization(s)]. [Name of individual] owns patent [patent identifier information (including patent number, two-letter country code, and kind code) and a brief description].

### Signed conflict of interest statement

**Title of paper:** Acute upper gastrointestinal bleeding associated with alcoholic liver disease or cirrhosis, but not directly related to portal hypertension: peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome

**Journal:** World Journal of Gastroenterology    **ID:** 00029272

Dr. Borko Nojkov declares no conflict of interest. Regarding Dr. Cappell, this paper does not discuss any confidential pharmaceutical data reviewed by Dr. Cappell as a consultant for the United States Food and Drug Administration (FDA) Advisory Committee on Gastrointestinal Drugs. Dr. Cappell is a member of the speaker's bureau for AstraZeneca. This work does not discuss any drugs produced or marketed by AstraZeneca. Dr. Cappell, therefore, declares no conflict of interest.

*B. Nojkov*

*7/28/2015*

Dr. Borko Nojkov

Date

*Mitchell S. Cappell*

*7/28/15*

Dr. Mitchell S. Cappell

Date